188 related articles for article (PubMed ID: 26160006)
1. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.
Venderbos LD; Roobol MJ; Bangma CH; van den Bergh RC; Bokhorst LP; Nieboer D; Godtman R; Hugosson J; van der Kwast T; Steyerberg EW
World J Urol; 2016 Feb; 34(2):253-60. PubMed ID: 26160006
[TBL] [Abstract][Full Text] [Related]
2. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
3. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
4. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
[TBL] [Abstract][Full Text] [Related]
5. A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance.
O'Brien BA; Cohen RJ; Ryan A; Sengupta S; Mills J
J Urol; 2011 Nov; 186(5):1811-7. PubMed ID: 21944097
[TBL] [Abstract][Full Text] [Related]
6. Can nomograms improve our ability to select candidates for active surveillance for prostate cancer?
Iremashvili V; Manoharan M; Parekh DJ; Punnen S
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):385-389. PubMed ID: 27431497
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
8. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer.
Wang SY; Cowan JE; Cary KC; Chan JM; Carroll PR; Cooperberg MR
BJU Int; 2014 Dec; 114(6b):E18-E24. PubMed ID: 24712895
[TBL] [Abstract][Full Text] [Related]
9. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
[TBL] [Abstract][Full Text] [Related]
10. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
Reese AC; Landis P; Han M; Epstein JI; Carter HB
J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
[TBL] [Abstract][Full Text] [Related]
11. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
12. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
[TBL] [Abstract][Full Text] [Related]
13. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
[TBL] [Abstract][Full Text] [Related]
14. PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance.
Cantiello F; Russo GI; Cicione A; Ferro M; Cimino S; Favilla V; Perdonà S; De Cobelli O; Magno C; Morgia G; Damiano R
World J Urol; 2016 Apr; 34(4):485-93. PubMed ID: 26194612
[TBL] [Abstract][Full Text] [Related]
15. The contemporary concept of significant versus insignificant prostate cancer.
Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
[TBL] [Abstract][Full Text] [Related]
16. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
[TBL] [Abstract][Full Text] [Related]
17. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
18. Active surveillance criteria for prostate cancer: can they be applied to Japanese patients?
Goto Y; Nozumi K; Miyazaki K; Matsumoto A; Inoue A; Kito H; Hasegawa N; Nagata M; Kakuta Y; Suzuki H; Yamaguchi K
Int J Urol; 2012 Feb; 19(2):163-6. PubMed ID: 22070372
[TBL] [Abstract][Full Text] [Related]
19. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
20. Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment.
Ting F; van Leeuwen PJ; Delprado W; Haynes AM; Brenner P; Stricker PD
Prostate; 2015 Nov; 75(15):1768-73. PubMed ID: 26282713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]